Uncertainty over Research and Development Investment Outcomes
First written in FY2016. 5 of 6 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 14 of 29 companies on the "Worse" side.
74 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「However, the results of research and development are uncertain, and there is a risk that substantial spending will not necessarily lead to results.」
The company again identifies the risk that results are uncertain, while investing an amount equivalent to approximately 10% of product sales in research and development expenses. - FY2025RestatedAnnual report
「Each fiscal year, we invest an amount equivalent to approximately 10% of product sales in research and development expenses. However, the results of research and development are uncertain, and there is a risk that substantial spending will not necessarily lead to results.」
The company again identifies the risk that research and development results are uncertain, while investing approximately 10% of product sales in research and development expenses. - FY2020RestatedAnnual report
「Each fiscal year, we invest an amount equivalent to approximately 10% of product sales in research and development expenses. However, the results of research and development are uncertain, and there is a risk that substantial spending will not necessarily lead to results.」
The company again identifies the risk that investment may not lead to results, while investing approximately 10% of product sales in research and development expenses. - FY2019RestatedAnnual report
「Each fiscal year, we invest an amount equivalent to approximately 10% of product sales in research and development expenses. However, the results of research and development are uncertain, and there is a risk that substantial spending will not necessarily lead to results.」
The company again identifies the risk that investment may not lead to results, while investing approximately 10% of product sales in research and development expenses. - FY2017RestatedAnnual report
「Each fiscal year, we invest an amount equivalent to approximately 10% of product sales in research and development expenses. However, the results of research and development are uncertain, and there is a risk that substantial spending will not necessarily lead to results.」
The company again identifies the risk that research and development investment may not lead to results, while investing approximately 10% of product sales in research and development expenses. - FY2016First statedAnnual report
「Each fiscal year, we invest an amount equivalent to approximately 10% of product sales in research and development expenses. However, the results of research and development are uncertain, and there is a risk that substantial spending will not necessarily lead to results.」
First reported. While investing approximately 10% of product sales in research and development expenses, the company explicitly identifies the risk that spending may not lead to results.